For patients at JosephCareRX who struggle with achieving adequate glycemic control through other treatments, Tirzepatide offers a promising alternative with its dual action on GIP and GLP-1 receptors, potentially providing enhanced benefits
National metabolic programs have integrated semaglutide into dual-management pathways for obesity and hypertension
Losartan, a selective antagonist of AT1 receptor, attenuates seawater inhalation induced lung injury via modulating JAK2/STATs and apoptosis in rat
In July 2025, we announced new data from Week 156 of our Phase 3 PaTHway Trial, confirming that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism regardless of its cause (post-surgical, autoimmune, genetic, or idiopathic), including improvements in biochemistries, kidney function, and quality of life
You can read the full article at Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial PMC (nih.gov)